Literature DB >> 26464483

A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease.

Mar Puigdellívol1, Marta Cherubini1, Verónica Brito1, Albert Giralt1, Núria Suelves1, Jesús Ballesteros2, Alfonsa Zamora-Moratalla2, Eduardo D Martín2, Betty A Eipper3, Jordi Alberch1, Silvia Ginés4.   

Abstract

Cognitive dysfunction is an early clinical hallmark of Huntington's disease (HD) preceding the appearance of motor symptoms by several years. Neuronal dysfunction and altered corticostriatal connectivity have been postulated to be fundamental to explain these early disturbances. However, no treatments to attenuate cognitive changes have been successful: the reason may rely on the idea that the temporal sequence of pathological changes is as critical as the changes per se when new therapies are in development. To this aim, it becomes critical to use HD mouse models in which cognitive impairments appear prior to motor symptoms. In this study, we demonstrate procedural memory and motor learning deficits in two different HD mice and at ages preceding motor disturbances. These impairments are associated with altered corticostriatal long-term potentiation (LTP) and specific reduction of dendritic spine density and postsynaptic density (PSD)-95 and spinophilin-positive clusters in the cortex of HD mice. As a potential mechanism, we described an early decrease of Kalirin-7 (Kal7), a guanine-nucleotide exchange factor for Rho-like small GTPases critical to maintain excitatory synapse, in the cortex of HD mice. Supporting a role for Kal7 in HD synaptic deficits, exogenous expression of Kal7 restores the reduction of excitatory synapses in HD cortical cultures. Altogether, our results suggest that cortical dysfunction precedes striatal disturbances in HD and underlie early corticostriatal LTP and cognitive defects. Moreover, we identified diminished Kal7 as a key contributor to HD cortical alterations, placing Kal7 as a molecular target for future therapies aimed to restore corticostriatal function in HD.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26464483      PMCID: PMC4664166          DOI: 10.1093/hmg/ddv426

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  95 in total

Review 1.  Dynamic aspects of CNS synapse formation.

Authors:  A Kimberley McAllister
Journal:  Annu Rev Neurosci       Date:  2007       Impact factor: 12.449

2.  Kalirin is under-expressed in Alzheimer's disease hippocampus.

Authors:  HyeSook Youn; MyoungKun Jeoung; YongBum Koo; Hanlee Ji; William R Markesbery; Inhae Ji; Tae H Ji
Journal:  J Alzheimers Dis       Date:  2007-06       Impact factor: 4.472

3.  Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.

Authors:  A Giralt; M Puigdellívol; O Carretón; P Paoletti; J Valero; A Parra-Damas; C A Saura; J Alberch; S Ginés
Journal:  Hum Mol Genet       Date:  2011-11-24       Impact factor: 6.150

4.  Kalirin-7 mediates cocaine-induced AMPA receptor and spine plasticity, enabling incentive sensitization.

Authors:  Xiaoting Wang; Michael E Cahill; Craig T Werner; Daniel J Christoffel; Sam A Golden; Zhong Xie; Jessica A Loweth; Michela Marinelli; Scott J Russo; Peter Penzes; Marina E Wolf
Journal:  J Neurosci       Date:  2013-07-03       Impact factor: 6.167

Review 5.  Experimental models of HD and reflection on therapeutic strategies.

Authors:  Jinho Kim; Olivia L Bordiuk; Robert J Ferrante
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

6.  Stably maintained dendritic spines are associated with lifelong memories.

Authors:  Guang Yang; Feng Pan; Wen-Biao Gan
Journal:  Nature       Date:  2009-11-29       Impact factor: 49.962

7.  Development of neuropsychological deficits in Huntington's disease.

Authors:  R C Josiassen; L M Curry; E L Mancall
Journal:  Arch Neurol       Date:  1983-12

8.  Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression.

Authors:  A Giralt; T Rodrigo; E D Martín; J R Gonzalez; M Milà; V Ceña; M Dierssen; J M Canals; J Alberch
Journal:  Neuroscience       Date:  2008-11-21       Impact factor: 3.590

9.  Kalirin-7 is required for synaptic structure and function.

Authors:  Xin-Ming Ma; Drew D Kiraly; Eric D Gaier; Yanping Wang; Eun-Ji Kim; Eric S Levine; Betty A Eipper; Richard E Mains
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

10.  Learning improvement after PI3K activation correlates with de novo formation of functional small spines.

Authors:  Lilian Enriquez-Barreto; Germán Cuesto; Nuria Dominguez-Iturza; Elena Gavilán; Diego Ruano; Carmen Sandi; Antonio Fernández-Ruiz; Gonzalo Martín-Vázquez; Oscar Herreras; Miguel Morales
Journal:  Front Mol Neurosci       Date:  2014-01-02       Impact factor: 5.639

View more
  20 in total

1.  Early Downregulation of p75NTR by Genetic and Pharmacological Approaches Delays the Onset of Motor Deficits and Striatal Dysfunction in Huntington's Disease Mice.

Authors:  Nuria Suelves; Andrés Miguez; Saray López-Benito; Gerardo García-Díaz Barriga; Albert Giralt; Elena Alvarez-Periel; Juan Carlos Arévalo; Jordi Alberch; Silvia Ginés; Verónica Brito
Journal:  Mol Neurobiol       Date:  2018-05-27       Impact factor: 5.590

2.  Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration.

Authors:  Jordi Creus-Muncunill; Laura Rué; Rafael Alcalá-Vida; Raquel Badillos-Rodríguez; Joan Romaní-Aumedes; Sonia Marco; Jordi Alberch; Isabel Perez-Otaño; Cristina Malagelada; Esther Pérez-Navarro
Journal:  Mol Neurobiol       Date:  2018-02-19       Impact factor: 5.590

3.  Cdk5 Contributes to Huntington's Disease Learning and Memory Deficits via Modulation of Brain Region-Specific Substrates.

Authors:  Elena Alvarez-Periel; Mar Puigdellívol; Verónica Brito; Florian Plattner; James A Bibb; Jordi Alberch; Silvia Ginés
Journal:  Mol Neurobiol       Date:  2017-12-29       Impact factor: 5.590

4.  Differential Effects of Sevoflurane Exposure on Long-Term Fear Memory in Neonatal and Adult Rats.

Authors:  Changsheng Li; Sufang Liu; Yixin Mei; Qingyong Wang; Xihua Lu; Hongle Li; Feng Tao
Journal:  Mol Neurobiol       Date:  2022-02-24       Impact factor: 5.590

5.  Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington's disease mice.

Authors:  Silvia Ginés; Verónica Brito; Anika Pupak; Ankita Singh; Anna Sancho-Balsells; Rafael Alcalá-Vida; Marc Espina; Albert Giralt; Eulàlia Martí; Ulf Andersson Vang Ørom
Journal:  Cell Mol Life Sci       Date:  2022-07-11       Impact factor: 9.207

Review 6.  Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.

Authors:  Jordi Creus-Muncunill; Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

7.  Pharmacological Modulators of Small GTPases of Rho Family in Neurodegenerative Diseases.

Authors:  William Guiler; Addison Koehler; Christi Boykin; Qun Lu
Journal:  Front Cell Neurosci       Date:  2021-05-12       Impact factor: 5.505

8.  Using Kalirin conditional knockout mice to distinguish its role in dopamine receptor mediated behaviors.

Authors:  Taylor P LaRese; Yan Yan; Betty A Eipper; Richard E Mains
Journal:  BMC Neurosci       Date:  2017-05-23       Impact factor: 3.288

Review 9.  Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity.

Authors:  Adelaide Tousley; Kimberly B Kegel-Gleason
Journal:  J Huntingtons Dis       Date:  2016-06-28

10.  A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.

Authors:  Nuria Suelves; Lucy Kirkham-McCarthy; Robert S Lahue; Silvia Ginés
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.